Trials / Completed
CompletedNCT00457795
24-hour IOP-lowering Effect of Brimonidine 0.1%
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 40 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the efficacy and safety of brimonidine 0.1% three-times daily in patients with glaucoma or ocular hypertension
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | brimonidine 0.1% (Alphagan® P) | Brimonidine 0.1%, 1 drop three-times daily for 4 weeks |
Timeline
- Start date
- 2006-12-01
- Primary completion
- 2009-02-01
- Completion
- 2009-02-01
- First posted
- 2007-04-09
- Last updated
- 2011-11-24
- Results posted
- 2011-11-24
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00457795. Inclusion in this directory is not an endorsement.